Back to GetFilings.com

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

                    For quarterly period ended September 30, 2004

Commission File Number:    0-16594

             Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.   |X|   Yes      [  ]    No

             Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    [  ]   Yes      [X]    No

             As of September 30, 2004, the registrant had 5,679,634 shares of common stock, $.01 par value per share, issued and outstanding.

MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES

Index

i.

Table of Contents

Item 1.     Financial Statements

PART 1 - FINANCIAL INFORMATION

MTS MEDICATION TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands)

ASSETS

LIABILITIES AND STOCKHOLDERS' EQUITY

The accompanying notes are an integral part of these financial statements.

1

Table of Contents

MTS MEDICATION TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(In Thousands; Except Earnings Per Share Amounts)

(Unaudited)

The accompanying notes are an integral part of these financial statements.

2

Table of Contents

MTS MEDICATION TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
SIX MONTHS ENDED SEPTEMBER 30, 2004
(In Thousands)
(Unaudited)

The accompanying notes are an integral part of these financial statements.

3

Table of Contents

MTS MEDICATION TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)

The accompanying notes are an integral part of these financial statements.

Supplemental Disclosure of Cash Flow Information

September 30, 2004
    Non-Cash Activities - Reclassification of approximately $66,000 in machine rentals from inventory to equipment as of September 30, 2004

September 30, 2003
    Non-Cash Financing Activities - The Company purchased $199,000 in equipment and financed the purchase with a capital lease obligation.

4

Table of Contents

MTS MEDICATION TECHNOLOGIES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2004

NOTE A – BASIS OF PRESENTATION

        The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six-month period ended September 30, 2004 are not necessarily indicative of the results that may be expected for the year ended March 31, 2005. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2004.

        The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, MTS Packaging Systems, Inc. (“MTS Packaging”) and MTS Medication Technologies, Ltd. (“MTSL”). All other subsidiaries of the Company did not have operations during the six-month period ended September 30, 2004 and 2003.

Accounting for the Transfer Pricing Effect on Inventory

        During the second quarter of 2005, the Company determined that the intercompany transfer price mark-up on inventory sent to the UK for sale into that market was not eliminated from the period-end inventory values. The cumulative effect as of the year ended March 31, 2004 would have been a reduction in pretax income of approximately $75,000. The cumulative effect as of the quarter ended June 30, 2004 would have been an increase in the pretax loss of approximately $134,000. The cumulative impact is reflected in the results for the three months ended September 30, 2004. Management does not believe that the impact of this adjustment is material to the March 31, 2004 financial statements from a quantitative and qualitative perspective, or to the projected operating results and earnings trend for the year ending March 31, 2005.

Reclassification of Certain Amounts

        Certain amounts on the consolidated balance sheet as of March 31, 2004 have been reclassified to conform to the September 30, 2004 presentation. During the three months ended September 30, 2004, the Company refined its classification of outstanding disbursements on the accompanying condensed consolidated balance sheets. This refinement resulted in a reclassification of March 31, 2004 amounts of approximately $640,000 from long-term debt to a component of accounts payable and accrued liabilities. In addition, the Company refined its classification of certain machinery on rent with customers on the accompanying condensed consolidated balance sheets, which resulted in a reclassification of March 31, 2004 amounts of approximately $114,000 from inventories, net to a component of property and equipment, net. The Company does not believe that the reclassifications have a material effect on the March 31, 2004 financial statements, both from a quantitative and qualitative perspective.

NOTE B – INVENTORIES

        The components of inventory consist of the following:

5

Table of Contents

NOTE C – EARNINGS PER SHARE

        Earnings per share are computed using the basic and diluted calculations on the face of the statement of operations. Basic earnings per share are calculated by dividing net income by the weighted average number of shares of common stock outstanding for the period and any warrants outstanding that are exercisable at a de minimus amount. Diluted earnings per share is calculated by dividing net income by the weighted average number of shares of common stock outstanding for the period, adjusted for the dilutive effect of common stock equivalents, using the “treasury stock” method and the “if converted” method as it relates to the convertible preferred stock outstanding.

        The following table sets forth the computation of income (loss) per basic and diluted common share:

        Certain provisions of the convertible preferred stock issued in June 2002 may result in the issuance of additional shares at some future date if certain events occur. Since these events have not yet occurred, and therefore the number of additional shares is not known, no additional shares have been included in the earnings per share calculation (see Note I).

6

Table of Contents

        The effect of outstanding options and warrants of approximately 717,000 shares and the effect of 847,000 shares of common stock that would be issued upon the conversion of the convertible preferred stock have not been included in the calculation of the loss per common share for the six months ended September 30, 2004 because their effect would have been anti-dilutive.

NOTE D – STOCK BASED COMPENSATION

        The Company follows only the disclosure provisions of SFAS No. 123, “Accounting for Stock-Based Compensation,” as it relates to employment awards. It applies APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and SFAS No. 148, “Accounting for Stock Based Compensation-Transition and Disclosure,” and related interpretations in accounting for its plans and does not recognize compensation expense based upon the fair value at the grant date for awards under these plans. If the Company had followed the methodology prescribed by SFAS 123, the Company’s net income and earnings per share would be reduced to the pro forma amounts indicated below:

7

Table of Contents

NOTE E – REVENUE RECOGNITION

        The Company recognizes revenue on the sale of machines, other than OnDemand® machines, and all disposables when products are shipped and title transfers. The Company recognizes revenue related to the sale of its OnDemand machines as prescribed in SOP 97-2 “Software Revenue Recognition” because the software component of the OnDemand machine is significant and not incidental to the value and functionality of the machine. In addition, the sale of an OnDemand machine represents an arrangement that encompasses multiple deliverables and therefore each deliverable represents a separate unit of accounting. The separate deliverables are comprised of (a) the OnDemand machine installed at the customer’s location; (b) the user training; and (c) certain component parts that are sold separately, principally cassettes that hold medications. The vendor specific fair value of the deliverables outlined in (b-c) has been determined based upon the value of these deliverables if they were sold separately. The fair value of the deliverable outlined in (a) has been determined using the residual method which equals the total selling price of the OnDemand machine, including installation, training and cassettes, less the aggregate fair value of (b-c). The terms of the sale arrangement for an OnDemand machine is typically FOB shipping point, at which time title and risk of loss transfers to the customer, however, because the installation of the machine is essential to the functionality of the machine the recognition of any of the revenue associated with the machine is deferred until the machine is installed. For those cassettes that are provided to the customer after the OnDemand machine is installed, the revenue associated with those cassettes is recognized upon their delivery. The Company recognizes the revenue associated with the training when performed.

        Revenue includes certain amounts invoiced to customers for freight and handling charges. The Company includes the actual cost of freight and handling incurred in cost of sales.

NOTE F – RESEARCH AND DEVELOPMENT AND PRODUCT DEVELOPMENT

        The Company expenses product research and development costs as incurred. The Company incurred approximately $48,000 in the three months ended September 30, 2004 compared to $66,000 in the prior year and $104,000 in the six months ended September 30, 2004 compared to $99,000 in the prior year.

        All costs incurred subsequent to the completion of research and development activities associated with the product’s hardware components and the software components achievement of technological feasibility are capitalized until the product is available for general release to customers. The Company initially classifies the construction costs of the first units produced for commercial use as product development costs prior to transferring these costs to inventory. The Company capitalized approximately $112,000 in the three months ended September 30, 2004 compared to $115,000 in the prior year and $156,000 in the six months ended September 30, 2004 compared to $253,000 in the prior year.

        Product development costs are generally amortized on a straight-line basis over a five (5) year period. Amortization expense related to product development costs was $81,000 for the three months ended September 30, 2004 compared to $91,000 in the prior year and $163,000 for the six months ended September 30, 2004 compared to $182,000 in the prior year.

        The Company’s capitalized product development costs included its new OnDemand product and versions thereof, which represented $1,725,000 at September 30, 2004 and $1,675,000 at March 31, 2004 (excluding accumulated amortization) of the total capitalized product development costs (see Note K).

8

Table of Contents

NOTE G – LONG-TERM DEBT

        The revolving line of credit and bank term loans are collateralized by a first security interest in all of the assets of the Company.

        There was $4.9 million borrowed and an additional $2.9 million available on the Company’s revolving line of credit at September 30, 2004 based upon eligible collateral and overadvance capabilities provided for in the credit facility.

        The bank term loans also contain provisions that require the Company to maintain certain financial ratios and minimum stockholders’ equity levels. In addition, certain provisions limit the amount of capital expenditures that the Company can make each year. The Company was in compliance with all provisions of the loan agreements as of September 30, 2004.

        At September 30, 2004, the Company also had a $300,000 line of credit available for purchases of equipment at an interest rate of prime plus .75%. Advances on the line of credit are repayable over a three-year term. There were no amounts outstanding on this line of credit at September 30, 2004.

        In June 2004, the Company repaid $4,000,000, the entire outstanding balance of its subordinated note, which was due in June 2007, with the proceeds of an additional term loan and advances on its revolving line of credit. At the time of the repayment, the carrying value of the note was $3,259,000. The remaining amount of $741,000 represented the balance of the original issue discount (“OID”) associated with the warrants that were issued to the holder of the note in June 2002. This OID was being amortized over the term of the note (five years), however, when the note was completely repaid, the remaining amount was amortized.

9

Table of Contents

        The Company incurred a prepayment penalty of $120,000 when the note was repaid, and this amount was recorded as additional interest expense.

NOTE H – CONTINGENCIES

        In November 1998, MTL, a discontinued operation, received a refund request in the amount of $1.8 million from Medicare Program Safeguards (“MPS”). MTL disputed the refund request in its response to MPS in December 1998. To date, MTL has not received any further correspondence from MPS regarding this matter.

        The Company is involved in certain claims and legal actions arising in the ordinary course of business including the matter referred to above. There can be no assurances that these matters will be resolved on terms acceptable to the Company. In the opinion of management, based upon advice of counsel and consideration of all facts available at this time, the ultimate disposition of these matters are not expected to have a material adverse effect on the financial position, results of operations or liquidity of the Company.

NOTE I – STOCKHOLDER EQUITY

        In June 2002, the Company issued subordinated notes to an investor (see Note G). As part of the consideration for the notes, the investor received 566,517 warrants to purchase common stock exercisable at $.01 per share for ten (10) years. The value of the warrants was determined as of the date of issuance using the Black-Scholes options-pricing model. In addition, an independent third party estimated the value of certain embedded features contained in the warrant agreement and registration rights agreement between the Company and the warrant holder (a “make-whole” and “claw-back” feature that obligated the Company to pay additional amounts, in cash or additional shares at the option of the Company, if certain events occurred in the future). Using the relative value of the debt ($4,000,000), warrants ($1,564,000) and the warrant’s embedded features ($233,000), the Company recorded the value of the warrants and the warrant’s embedded features as part of its stockholders equity, in accordance with EITF 00-19, and reduced the carrying amount of the debt as an original issue discount. The original issue discount, $1,240,000, was being amortized over the five year term of the subordinated notes and a corresponding increase in the carrying value of the subordinated notes.

        In April 2004, the investors exercised their rights to acquire 566,517 shares of common stock under the terms of the warrant agreement and sold the common stock. The terms of the warrant agreement contained certain anti-dilution provisions. The warrant agreement also contained a make-whole provision that obligated the Company to pay certain amounts to the holders of the warrants if they did not ultimately receive an amount equal to the price per share of the common stock on the date they exercise their right to purchase the common shares that underlie the warrants. The warrant agreement also contained a provision that may have obligated the Company to pay certain amounts to the holders of the warrants in the event there was a change in control of the voting common stock of the Company, if there was a sale of the Company, or if there was a public offering of the Company’s common stock. All of the Company’s obligations under the warrant agreement, described above, were extinguished at the time the investor sold the common stock, and the subordinated note was repaid (see Note G).

10

Table of Contents

        In June 2002, the Company issued 2,000 shares of convertible preferred stock at $1,000 per share. The holders of the convertible preferred stock are entitled to receive quarterly dividends at the rate of 11% per annum. The dividends are payable in cash or shares of convertible preferred stock at the Company’s option and are cumulative. Through the period ended March 31, 2004, all dividends were paid in cash. The preferred stock is convertible into 847,457 shares of the Company’s common stock at $2.36 per share. On the date the convertible preferred stock was issued, the fair market value of the Company’s common stock was $2.77 per share based upon the closing bid on the OTC Bulletin Board. The difference between the fair market value of the shares and the conversion price of the convertible preferred stock represented a constructive dividend to the holders of the preferred stock in the amount of $347,000. The terms of the convertible preferred stock agreement contains certain anti-dilution provisions and also contains a make-whole provision that obligates the Company to pay certain amounts to the holder of the convertible preferred stock if they do not ultimately receive an amount equal to the price per share of the common stock on the date they exercise their right to convert the convertible preferred stock into common stock. The Company followed the accounting prescribed in EITF 98-5 and EITF 00-27 for the recording of the convertible preferred stock and the constructive dividend.

        The make-whole provision and certain anti-dilution provisions also represent a contingent beneficial conversion feature of the convertible preferred stock. The effect of this feature may result in the issuance of additional shares of common stock at some future date; however, since the issuance of these shares is contingent on future events, the effect of this feature will be recorded at the time the events occur. In addition, if the holder of the preferred stock receives a certain multiple of its investment once the convertible preferred shares are converted into common stock and the common stock is subsequently sold, the make-whole provision is no longer applicable.

        In the event that the Company is required to make payments to the holders of the convertible preferred stock, it may elect to issue additional convertible preferred stock in lieu of a cash payment. Although the make-whole provision and other provisions of the convertible preferred stock agreement provide for a maximum of 12,500,000 shares of common stock that may be issued pursuant to those provisions, based upon current conditions, the Company believes it is unlikely that the maximum number of shares would be issued.

        During September 2004, the Company issued 50,000 common shares that are restricted under the Securities and Exchange Commission Rule 144 to its former Chief Financial Officer as remaining compensation under his employment agreement.  The restriction on the common shares lapses on January 1, 2005.  The Company recorded compensation expense in the amount of $351,500 during the three months ended September 30, 2004 based on the fair value of the shares at the grant date.

NOTE J – FINANCING COSTS

        During fiscal year 2003, the Company incurred approximately $1,458,000 of financing costs including the value of the warrants issued to the Company’s financial advisors related to obtaining certain financing described in Notes G and I. The financing costs were allocated between the components of the financing that represented debt and equity. The financing costs that were allocated to the debt proceeds, $1,090,000, have been recorded as other assets and have been amortized over the repayment term of the various loans and notes. The financing costs that were allocated to the equity proceeds, $368,000, were recorded as a reduction of the equity proceeds. In June 2004, the Company completely repaid the outstanding loans that were obtained in fiscal year 2003. As a result, financing costs in the amount of $420,000 that were allocated to these loans that remained on the date the loans were completely repaid were completely amortized. The loans were repaid with the proceeds of a new term loan and advances on a revolving line of credit. During the period ended June 30, 2004, the Company incurred $95,000 of financing costs associated with the new financing. These costs have been recorded as other assets and will be amortized over the three-year term of the new loans.

11

Table of Contents

NOTE K – OTHER ASSETS

        Other assets consists of the following:

        All of the Company’s intangible assets are pledged as collateral on bank notes.

NOTE L – RELATED PARTY TRANSACTIONS

        On July 28, 2003, the Company entered into an Asset Purchase Agreement with the Siegel Family Trust (the “Trust”) to purchase the rights to certain proprietary technology that had previously been available to the Company through a license agreement between the Company and the Trust. In order to assist the Company in determining the appropriate value of the rights to the proprietary technology, the Board of Directors formed a special committee comprised of three outside independent directors. The special committee engaged an independent third party who appraised the value of the proprietary technology at $1,132,000. As part of the agreement, the Trust agreed to terminate the license agreement. The purchase price of the appraised amount of the proprietary technology and $348,000 of accrued and unpaid royalties will be paid to the Trust in the form of a promissory note that is payable in sixty (60) monthly payments of $28,785, beginning on August 1, 2003, including interest at the rate of 6.25%. The Company reduced the purchase price of the rights by the amount of the unpaid royalties and recorded the resulting amount as patents. The patents will be amortized over a five-year period, which represents the remaining life of the patents related to these rights. The amortization expense related to these patents for the six months ended September 30, 2004 and 2003 was approximately $113,000, and $38,000, respectively.

12

Table of Contents

NOTE M – LEASE COMMITMENTS

        The Company currently leases a 79,600 square foot plant consisting of office, manufacturing and warehousing space. On March 31, 2004, the Company provided its landlord with notice of intent to terminate this lease on October 31, 2004. Effective October 1, 2004, the Company will occupy the new premises. The lease for the new premises will be for a term of twelve (12) years. The premises consists of approximately 132,000 square feet, and the monthly lease payments begin at $35,000 plus tax in the first year and increases to $80,270 plus tax in the final year. In addition, the Company is obligated to pay annual operating expenses, i.e., insurance, taxes and common area maintenance fees. The Company was paid a move-in allowance, by the landlord, of $400,000 on the commencement date of the lease, which will be amortized over the remaining term of the current lease. In addition, the Company has accelerated the amortization of approximately $237,000 associated with the abandonment of leasehold improvements that were made to the current premises over the remaining life of the current lease. Also, the Company expects to incur approximately $350,000 in costs associated with the move to the new facility and expenses associated with bringing the current premises into a condition acceptable to the landlord. Although an estimate cannot be reasonably made, management does not believe these costs will have a material impact on the financial statements. The moving expenses are expected to be recorded in the third quarter of this fiscal year.

        The Company also leases approximately 5,200 square feet of office and warehouse space in Cleveland, Ohio at $3,200 per month. The lease expires on March 31, 2005.

        One of the Company’s subsidiaries, MTS Medication Technologies, Ltd., rents office and warehouse space in Lancashire, England at £1,929 per month, which as of September 30, 2004, is equivalent to approximately $3,490. This lease is for a term of one year.

13

Table of Contents

MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2004

ITEM 2.     MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

        References in this Form 10-Q to the “Company,” “MTS,” “we,” “our” or “us” means MTS Medication Technologies, Inc., together with its subsidiaries, except where the context otherwise indicates. This Form 10-Q contains forward-looking statements within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Additional written or oral forward-looking statements may be made by us from time to time, in filings with the Securities and Exchange Commission or otherwise. Statements contained herein that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions described above. Forward-looking statements may include, but are not limited to, projections of revenues, income or losses, capital expenditures, plans for future operations, the elimination of losses under certain programs, financing needs or plans, compliance with financial covenants in loan agreements, plans for sale of assets or businesses, plans relating to our products or services, assessments of materiality, predictions of future events and the effects of pending and possible litigation, as well as assumptions relating to the foregoing. In addition, when used in this discussion, the words “anticipates”, “estimates”, “expects”, “intends”, “believes”, “plans” and variations thereof and similar expressions are intended to identify forward-looking statements.

        Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified based on current expectations. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements contained herein. Statements in Quarterly Reports, particularly in “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Notes to Condensed Consolidated Financial Statements, describe factors, among others, that could contribute to or cause such differences. Other factors that could contribute to or cause such differences include, but are not limited to, unanticipated increases in operating costs, labor disputes, capital requirements, increases in borrowing costs, product demand, pricing, market acceptance, intellectual property rights and litigation, risks in product and technology development and other risk factors detailed in our Securities and Exchange Commission filings. In particular any comments regarding possible default waivers related to our loan agreement are forward-looking statements.

        Readers are cautioned not to place undue reliance on any forward-looking statements contained herein, which speak only as of the date hereof. We undertake no obligation to publicly release the result of any revisions of these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unexpected events.

Summary of Results

        We experienced growth in revenue of 28% in the second quarter and 35% in the six months ended September 30, 2004 compared to the same periods of the prior year. Our revenue grew due to increased sales of our disposable products to existing and new customers and increased sales of our machines including the OnDemand® machine. We believe the revenue increase in our disposable products is the result of: (1) increased penetration of independent pharmacies and new markets; and (2) growth in market demands due to the aging demographics of the U.S. population.

14

Table of Contents

        The following table sets forth, for the three-month and six month periods indicated, certain key operating results and other financial information (in thousands, except per share data).

ESTIMATES AND CRITICAL ACCOUNTING POLICIES

        The preparation of our unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and revenues and expenses for the respective period-ended for such statements. The determination of estimates requires the use of judgment because future events and their affect on our operations cannot be determined with absolute certainty. Actual results typically differ from these estimates in some fashion, and at times, these variances may be material to our financial statements. Management continually evaluates its estimates and assumptions, which are based on historical experience and other factors that are believed to be reasonable under these circumstances. These estimates and our actual results are subject to the risk factors listed above under this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Nevertheless, our management believes the following items involve a higher degree of complexity and, judgment and therefore, has commented on these items below.

Revenue Recognition

        The Company recognizes revenue on the sale of machines, other than OnDemand machines, and all disposables when products are shipped and title transfers. The Company recognizes revenue related to the sale of its OnDemand machines as prescribed in SOP 97-2 “Software Revenue Recognition” because the software component of the OnDemand machine is significant and not incidental to the value and functionality of the machine. In addition, the sale of an OnDemand machine represents an arrangement that encompasses multiple deliverables and therefore each deliverable represents a separate unit of accounting. The separate deliverables are comprised of (a) the OnDemand machine installed at the customer’s location; (b) the user training; and (c) certain component parts that are sold separately, principally cassettes that hold medications. The vendor specific fair value of the deliverables outlined in (b-c) has been determined based upon the value of these deliverables if they were sold separately. The fair value of the deliverable outlined in (a) has been determined using the residual method which equals the total selling price of the OnDemand machine, including installation, training and cassettes, less the aggregate fair value of (b-c). The terms of the sale arrangement for an OnDemand machine is typically FOB shipping point, at which time title and risk of loss transfers to the customer, however, because the installation of the machine is essential to the functionality of the machine the recognition of any of the revenue associated with the machine is deferred until the machine is installed. For those cassettes that are provided to the customer after the OnDemand machine is installed, the revenue associated with those cassettes is recognized upon their delivery. The Company recognizes the revenue associated with the training when performed.

        Revenue includes certain amounts invoiced to customers for freight and handling charges. We include the actual cost of freight and handling incurred in cost of sales.

15

Table of Contents

Valuation of Accounts Receivable at September 30, 2004

        Our allowance for doubtful accounts of $227,000 at September 30, 2004 is based on management’s estimates of the credit-worthiness of our customers, current economic conditions and historical information. In the opinion of management, our allowance for doubtful accounts is believed to be an amount sufficient to respond to normal business conditions. Historically, the levels of recorded bad debt expense and write-offs have not been material to our financial statements. Should business conditions deteriorate or any large customer default on its obligations to us, this allowance may need to be significantly increased, which would have a negative impact upon our operations.

Inventory Obsolescence Valuation Allowance

        Our allowance for inventory obsolescence and slow moving inventory is reviewed on a monthly basis. We review various information related to the age and turnover of specific inventory items to assist in our assessment. In the opinion of management, the valuation allowance is believed to be sufficient to absorb the ultimate obsolescence of certain inventory as they may occur. The inventory obsolescence valuation allowance was $166,000 at September 30, 2004.

Self-Insurance Plan Reserve

        We have established a reserve for unpaid medical claims of $84,000 at September 30, 2004. Management reviews claims history information provided to it by the third-party administrator of the self insured plan on a regular basis and believes that the reserve is sufficient to respond to the claims that may be incurred by the participants in the plan.

Deferred Tax Asset Valuation Allowance

        Our deferred tax asset is comprised primarily of a tax loss carryforward. We believe that it is more likely than not that the income tax benefits associated with the tax loss carryforward will be realized in the future. Management bases this belief, in part, on the historical profitability of its operations and its expectations that profitable operations will continue in the future. Based upon these expectations regarding the realization of the tax benefits, management has not established a valuation allowance for its deferred tax asset.

Impairment Valuations

        On a quarterly basis, management assesses the composition of our assets and liabilities, as well as the events that have occurred and the circumstances that have changed since the most recent fair value determination. If events occur or circumstances change that would more likely than not reduce the fair value of the related asset or liability below its carrying amount, the related asset or liability would be tested for impairment.

        We evaluate the recoverability of our long-lived assets whenever circumstances indicate that the carrying amount of an asset may not be recoverable. Factors considered include current operating results, trends and anticipated undiscounted future cash flows. An impairment loss is recognized to the extent the sum of discounted (using our incremental borrowing rate) estimated future cash flows (over a period ranging from generally four to ten years) expected to result from the use of the asset is less than the carrying value. Management believes no impairment existed for any of the periods presented.

Product Development

        All costs incurred subsequent to the completion of research and development activities associated with a product’s hardware components and the software components achievement of technological feasibility are capitalized until the product is available for general release to customers. Product development costs are generally amortized over a five-year period beginning on the date the product is released for sale to customers. On a quarterly basis, we review the viability and recoverability of these project costs.

16

Table of Contents

Estimated Liabilities

        We make a number of estimates in the ordinary course of business. Historically, past changes to these estimates have not had a material impact on our financial condition. However, circumstances could change, which would alter future financial information based upon a change in estimated-vs.-actual results.

        We are subject to various matters of litigation in the ordinary course of business. As the outcome of any litigation is unknown, management estimates the potential amount of liability, if any, in excess of any applicable insurance coverage, based on historical experience and/or the best estimate of the matter at hand. Significant changes in estimated amounts could occur. To date, we have not had to pay any legal settlements in excess of existing insurance coverage.

Warranty

        We established a reserve for warranty costs that we may incur during the warranty period that is provided for in the OnDemand machine sales agreements with our customers. To date, warranty costs have not been material.

RESULTS OF OPERATIONS

Three Months Ended September 30, 2004 and 2003

        Net sales for the three months ended September 30, 2004 increased 28% to $10.2 million from $8.0 million during the same period in the prior fiscal year. Net sales increased primarily as a result of an increase in the amount of disposable punch cards and machines sold to new and existing customers. In addition, revenue associated with the sale of OnDemand machines was $0.8 million during the three months ended September 30, 2004 compared to $0.1 million in the same period in the prior year. Average selling prices for disposable products were stable during the second quarter of fiscal year 2005 compared to the same period in the prior fiscal year. The volume of disposable cards and machines is currently anticipated to continue to grow as a result of the addition of new customers in existing and new markets.

        Cost of sales for the three months ended September 30, 2004 increased 26% to $6.3 million from $5.0 million during the same period in the prior year. Cost of sales as a percentage of sales decreased to 61.3% from 62.2% during the same period in the prior fiscal year. Cost of sales as a percentage of sales decreased in the second quarter of fiscal year 2005 compared to the same period in the prior year primarily due to an improvement in efficiencies achieved in the manufacturing process for disposable products that were realized from new production equipment added in the fourth quarter of fiscal 2004.

        Selling, general and administration expenses for the three months ended September 30, 2004 increased 62% to $2.7 million from $1.7 million in the prior year primarily due to: (i) increased marketing expenses associated with our rebranding; (ii) increases in costs related to sales personnel compensation plans that are tied to increased revenue and the costs associated with senior management personnel that were added; and (iii) increases in legal and professional fees, many of which related to compliance with the Sarbanes-Oxley Act and related corporate governance issues. Also, employee benefit costs increased in the second quarter of this year compared with the second quarter of the previous year. The Company issued a 50,000 share restricted stock grant to its former Chief Financial Officer in the second quarter incurring a charge of $351,500.

        Depreciation and amortization expenses for the three months ended September 30, 2004 increased 71% to $527,000 from $309,000 during the same period of the prior year. The increase is primarily due to accelerating the amortization of leasehold improvements made to our current facility as a result of terminating our lease in anticipation of relocating in October 2004. In addition, we began to amortize the cost of the proprietary technology acquired from a related party in the second quarter of the prior fiscal year. There was limited amortization expense associated with this proprietary technology in the second quarter of the prior year.

17

Table of Contents

        Interest expense for the three months ended September 30, 2004 decreased 50% to $103,000 from $206,000 during the same period of the prior fiscal year. The decrease results primarily from lower interest rates due to the refinancing of the $4,000,000 subordinated note in June 2004.

        Amortization of original issue discount and financing costs decreased to $9,000 in the second quarter of this year compared to $147,000 in the second quarter of the prior fiscal year. The decrease resulted from the repayment of the $4,000,000 subordinated note in June 2004. At that time, the remaining original issue discount and financing costs associated with that note was completely amortized.

        We realized an income tax expense of $240,000 during the three months ended September 30, 2004 compared to $265,000 income tax expense during the same period in fiscal year 2004. The effective tax rate for the period ended September 30, 2004 compared with the second quarter of fiscal year 2004 remained the same.

Six Months Ended September 30, 2004 and 2003

        Net sales for the six months ended September 30, 2004 increased 35% to $20.3 million from $15.0 million during the same period in the prior fiscal year. Net sales increased primarily as a result of an increase in the amount of disposable punch cards and machines sold to new and existing customers. In addition, revenue associated with the sale of OnDemand machines was $2.4 million during the six months ended September 30, 2004 compared to $0.1 million in the same period of the prior fiscal year. Average selling prices for disposable products were stable during the first six months of fiscal 2005 compared to the same period in the prior fiscal year. The volume of disposable cards and machines is currently anticipated to continue to grow as a result of the addition of new customers in existing and new markets.

        Cost of sales for the six months ended September 30, 2004 increased 36% to $12.5 million from $9.2 million during the same period in the prior fiscal year. Cost of sales as a percentage of sales increased to 61.7% from 61.3% during the same period in the prior fiscal year. Cost of sales as a percentage of sales increased because the product cost of OnDemand machines as a percentage of sales is higher than the product cost of disposable punch cards and six OnDemand machines were sold in the first half of this year compared with one in the first half of the prior year.

        Selling, general and administration expenses for the six months ended September 30, 2004 increased 50% to $4.9 million from $3.3 million in the prior year primarily due to: (i) increased marketing expenses associated with our rebranding; (ii) increases in costs related to sales personnel compensation plans that are tied to increased revenue and the costs associated with senior management personnel that were added; and (iii) increases in legal and professional fees, many of which related to compliance with the Sarbanes-Oxley Act and related corporate governance issues. Also, employee benefit costs increased in the first six months of this year compared with the first six months of the previous year. In the second quarter, the Company issued a 50,000 share restricted stock grant to its former Chief Financial Officer incurring a charge of $351,500.

        Depreciation and amortization expenses for the six months ended September 30, 2004 increased 75% to $1,025,000 from $585,000 during the same period in the prior fiscal year. The increase is primarily due to accelerating the amortization of leasehold improvements made to our current facility as a result of terminating our lease in anticipation of relocating in October 2004. In addition, we began to amortize the cost of the proprietary technology acquired from a related party in the second quarter of the prior fiscal year. There was limited amortization expense associated with this proprietary technology in the first six months of the prior year.

        Interest expense for the six months ended September 30, 2004 increased 2% to $416,000 from $409,000 during the same period in the prior fiscal year. The increase results primarily from the fact that we incurred a $120,000 prepayment penalty when our $4,000,000 subordinated note was repaid in June 2004 offset in part by lower debt levels and lower interest rates on the new debt.

18

Table of Contents

        Amortization of original issue discount and financing costs increased to $1,287,000 for the first six months of this year compared with $295,000 in the first quarter of the prior year. The increase resulted from the repayment of the $4,000,000 subordinated note in June 2004. At that time, the remaining original issue discount and financing costs associated with that note was completely amortized.

        We realized an income tax expense of $150,000 during the six months ended September 30, 2004 compared to $470,000 income tax expense during the same period in the prior fiscal year. The decrease results from the fact that we had lower income before tax during the six-month period ended September 30, 2004 compared to the prior year. The increase in the effective tax rate for the period ended September 30, 2004 compared with the same period of the prior year resulted from the expense related to permanent difference between the carrying value of the subordinated debt for book and tax purposes due to the repayment of the subordinated debt in June 2004.

LIQUIDITY AND CAPITAL RESOURCES

        During the six months ended September 30, 2004, we had a net loss of $161,000 compared to net income of $663,000 during the same period in the prior fiscal year. Cash provided by operations was $2,931,000 during the six months ended September 30, 2004 compared to $1,406,000 provided during the same period in the prior fiscal year. We had working capital of $8,236,000 at September 30, 2004.

        The cash provided by operations during the six months ended September 30, 2004 consisted of $51,000 net operating loss, $2,312,000 of depreciation and amortization, $150,000 in income tax expense, $351,500 for restricted stock grant awarded, $794,000 in decreases in accounts receivable, $114,000 increase in accounts payable and accrued liabilities offset in part by a $708,000 increase in inventory and a $59,000 increase in prepaid expenses.

        Investing activities used $1,116,000 during six months ended September 30, 2004 compared to $731,000 during the same period in the prior fiscal year. The increase results primarily from an increase in expenditures in property and equipment associated with the move of our facilities.

        Financing activities used $1,708,000 during the six months ended September 30, 2004 compared to $945,000 the same period the prior year primarily due to reductions in long-term debt that resulted from cash provided by operations.

        Our short-term and long-term liquidity is primarily dependent on our ability to generate cash flow from operations. Inventory levels may change significantly if we are successful in selling our OnDemand machines. Increases in net sales may result in corresponding increases in accounts receivable. Cash flow from operations and borrowing availability on the revolving line of credit is anticipated to support an increase in accounts receivable and inventory.

        We have new product development projects underway, principally new versions of our OnDemand machine and our recently announced MedLocker™ system, that are expected to be funded by cash flow from operations. These projects are monitored on a regular basis to attempt to ensure that the anticipated costs associated with them do not exceed our ability to fund them from cash flow from operations and other sources of capital.

        There was $4.9 million borrowed and an additional $2.9 million available on our revolving line of credit at September 30, 2004 based upon eligible collateral and overadvance capabilities provided for in the credit facility. In addition, we had $300,000 available on our capital equipment line of credit.

19

Table of Contents

        The revolving line of credit, term loans and subordinated notes each contain financial covenants that, among other things, requires us to maintain certain financial ratios, tangible net worth and limits the amount of capital expenditures we can make. We were in compliance with all provisions of the loan agreements at September 30, 2004.

        We believe that the cash generated from operations during this fiscal year, and amounts available on our revolving line of credit, are expected to be sufficient to meet our capital expenditures, product development, working capital needs and the principal payments required by our term loan agreements.

Item 3.     Quantitative and Qualitative Disclosures About Market Risk

        There have been no material changes in our market risk during the six months ended September 30, 2004. Market risk information is contained under the caption “Quantitative And Qualitative Disclosures About Market Risk” of our annual report on Form 10-K for the fiscal year ended March 31, 2004 and is incorporated herein by reference.

Item 4.    Controls and Procedures

Evaluation of Disclosure Controls and Procedures

        We carried out an evaluation required by Rules 13a-15 and 15d-15 under the Securities Exchange Act of 1934 (the “Evaluation”), under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15 and 15d-15 promulgated under the Securities Exchange Act of 1934 (“Disclosure Controls”). Although we believe that our pre-existing Disclosure Controls were adequate to enable us to comply with our disclosure obligations, as a result of such Evaluation, we implemented minor changes, primarily to formalize, document and update the procedures already in place. Based on the Evaluation, our CEO and CFO concluded that, subject to the limitations noted below, our Disclosure Controls are effective in timely alerting them to material information required to be in our periodic Securities and Exchange Commission reports.

Changes in Internal Controls

        There has not been any change in our internal control over financial reporting identified in connection with the Evaluation that occurred during the quarter ended September 30, 2004 that has materially affected or is reasonably likely to materially affect, those controls.

Limitations on the Effectiveness of Controls

        Our management, including our CEO and CFO, does not expect that our Disclosure Controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.

20

Table of Contents

        The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events occurring. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, a control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Due to the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

CEO and CFO Certifications

        Exhibits 31.1 and 31.2 are Certifications of the CEO and the CFO, respectively. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the “Section 302 Certifications”). This Item of this report, which you are currently reading, is the information concerning the Evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

21

Table of Contents

PART II — OTHER INFORMATION

Item 6.    Exhibits

22

Table of Contents

Signatures

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

23

Table of Contents

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Todd E. Siegel, certify that:

    1.        I have reviewed this quarterly report on Form 10-Q of MTS Medication Technologies, Inc.;

    2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

    5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

24

Table of Contents

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Branca, certify that:

    1.        I have reviewed this quarterly report on Form 10-Q of MTS Medication Technologies, Inc.;

    2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

    4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

    5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

25

Table of Contents

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

        In connection with the quarterly report of MTS Medication Technologies, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2004, as filed with the Securities and Exchange Commission on the date hereof (the “Form 10-Q”), I, Todd E. Siegel, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

       (1)        The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. § 78m or 78o(d)); and

       (2)        The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

26

Table of Contents

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

        In connection with the quarterly report of MTS Medication Technologies, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2004, as filed with the Securities and Exchange Commission on the date hereof (the “Form 10-Q”), I, Michael Branca, Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

       (1)         The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or §78o(d)); and

       (2)         The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

27